Ledger.

Partner, Cauldron Ferm

Phil Morle

Coverage

Stories naming Phil Morle. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

3 deals

Regional biomanufacturer Cauldron brews up $19 million Series A2

Biomanufacturer Cauldron Ferm has banked a $19 million Series A2, led by Main Sequence with Horizons, SOSV and NGS Super aboard, adding to an earlier $9.5 million round and a $4.3 million federal grant.

Also SmartCompany·SmartCompany·Startup Daily·Startup Daily

Unnamed stage $158m

The founder of one of Main Sequence’s first investments, medtech Maxwell Plus, on failure, timing, and being ahead of the pack

A retrospective on Maxwell Plus, a machine-vision prostate cancer medtech that folded, with founder Elliot Smith and investor Phil Morle sharing lessons; Harrison.ai's later raise underscores the timing they missed.

Also Startup Daily·Startup Daily·SmartCompany·SmartCompany·Startup Daily·Startup Daily·Forbes Australia·Forbes Australia

3 deals

‘Game changer’: Samsara Eco raises $100 million for infinite recycling of plastics

Australian plastics recycler Samsara Eco secured a Temasek-led Series A+ of $100 million to scale enzyme-based infinite recycling, with Southeast Asian facilities planned, adding to its 2022 Series A.

Also TechCrunch Venture·SmartCompany·@AuManufacturing·Techboard·SmartCompany·@AuManufacturing·@AuManufacturing·@AuManufacturing

3 deals

Eden Brew raises $24.4 million to bring animal-free dairy products to market

Precision fermentation company Eden Brew raised a $24.4 million Series A led by Main Sequence, with Breakthrough Victoria and other backers, to commercialise animal-free dairy and relocate from Sydney to Melbourne.

Also @AuManufacturing·SmartCompany·Startup Daily·Startup Daily·Startup Daily·AgFunderNews·AgFunderNews·Crunchbase News

Funding announcement

Australia's regional areas lead the way in technological revolution

Feature on tech startups thriving outside Australian capitals, recording Cauldron's seed raise and government backing, with views from investors and founders at regional companies.

Key hire

Main Sequence announces new Partner, Gabrielle Munzer, to build companies with biology

Australia's Main Sequence fund promotes Gabrielle Munzer to Partner to lead its biotech push; the article also covers her finance background, the firm's company-building model, a UNSW accelerator, and recent diverse hires.

2 deals

This week on SUDS, the Startup Daily TV podcast: Tech on women's rights, MCB v AGL, how to raise $100m, what to do with fugly fruit

Preview of the Startup Daily TV podcast covering a bid against AGL's demerger, reproductive-rights tech policy, VC conversations, a fintech fund raise, and interviews with Skedulo, Good & Fugly and One Key Access founders.

Also Startup Daily·Dynamic Business

Unnamed stage $4m

CSIRO backs vegan 'milk' startup in $4 million project to brew fake dairy

Fermentation-based dairy startup Eden Brew launches with A$4 million from CSIRO, its venture fund Main Sequence, and dairy co-operative Norco, targeting its first animal-free milk product on shelves within 18 months.

Also SmartCompany·SmartCompany·SmartCompany·SmartCompany

Unnamed stage $11m

While other startups develop alt-proteins for meat replacement, Nourish Ingredients focuses on fat

Australian startup Nourish Ingredients, which engineers fats for plant-based meat, has raised $11 million from Horizons Ventures and Main Sequence Ventures. Founders Petrie and Leita met at CSIRO; the company employs 18 people.

Also SmartCompany·@AuManufacturing·Cut Through Venture·SmartCompany·SmartCompany·Startup Daily·AgFunderNews·AgFunderNews·@AuManufacturing·@AuManufacturing·@AuManufacturing·TechCrunch Venture

Seed

As Australia’s meat-free scene sizzles, Hungry Jack’s boss backs plant-based protein startup

Profile of plant-based meat startup v2food, created through CSIRO and Main Sequence Ventures, with seed backing from Jack Cowin's Competitive Foods Australia. Founder Nick Hazell discusses launch plans and the alternative protein market.

Something wrong? Tell us